#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Infertility female Liposarcoma metastatic Cholangitis sclerosing Heart disease congenital Pulmonary hypertension Gastrointestinal neuroendocrine tumour Fungal infection Shprintzen-Goldberg syndrome Kaposi's sarcoma Philadelphia positive acute lymphocytic leukaemia Craniocerebral injury B-cell small lymphocytic lymphoma recurrent Dermatitis Kawasaki's disease Small cell lung cancer recurrent More trials…

    Learn about Rare Diseases

    Bronchopulmonary dysplasia – Diagnostics Piriformis syndrome Soft tissue sarcoma Arterial tortuosity syndrome – Trials in Disease Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome – Diagnostics Splenic marginal zone lymphoma Nephrotic syndrome – Life with Disease Pituitary-dependent Cushing’s syndrome – Diagnostics Gaucher’s disease type III Breast angiosarcoma – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Anb032 Ziclumeran Montelukast Sodium Selumetinib FLUCLOXACILLIN SODIUM Pitolisant Artemisia Vulgaris Lerodalcibep TRV045 Sodium Sulfate Anhydrous Ifosfamide Cetrimide Nizatidine Sodium S-Lactate Solution GSKVX000000034797 Sodium Picosulfate Cemiplimab Ds-2325A Peginterferon Alfa-2A Calcium Folinate Pentahydrate More therapies…

    Learn about Your Condition

    Ischaemic skin ulcer Intracranial aneurysm End stage renal disease Anal abscess Haematological infection Guttate psoriasis Frostbite Stomatitis Lyme disease Hepatoblastoma Breast proliferative changes Methylmalonic acidaemia Pertussis Langerhans cell sarcoma Underweight More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Plasma cell myeloma

  • Cevostamab, Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 1‑3 Lines of Therapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Carfilzomib
    • Cevostamab
    • Daratumumab
    Czechia Denmark France Germany Greece Italy +2

  • Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Teclistamab
    • Bortezomib
    • Daratumumab
    Germany

  • A study of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in adults with newly diagnosed multiple myeloma not eligible for transplant

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Daratumumab
    • Dexamethasone
    • Lenalidomide
    France Norway Spain

  • A study testing etentamig alone or with drug combinations in adult patients with multiple myeloma to assess safety and changes in disease activity

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Carfilzomib
    • Daratumumab
    • Dexamethasone
    Norway

  • A Study of Linvoseltamab in Adult Patients with High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Hypergammaglobulinaemia benign monoclonal
    • Plasma cell myeloma
    Investigated Drugs:
    • Linvoseltamab
    • Dexamethasone Sodium Phosphate
    • Diphenhydramine Hydrochloride
    Belgium France Ireland Italy Poland Spain

  • Study of daratumumab, teclistamab and talquetamab combination treatment for frail patients with newly diagnosed multiple myeloma

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Talquetamab
    • Teclistamab
    • Daratumumab
    Italy The Netherlands Norway Spain
1 2 3 … 27
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!